U.S. Energy Services Stock News

NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Is Corvus Pharmaceuticals (CRVS) Now Attractive After Recent Share Price Volatility?

If you are wondering whether Corvus Pharmaceuticals' recent share price puts it at a bargain or a stretched level, you are not alone. This article is here to unpack what that current price might mean for value focused investors. The stock has been volatile, with a 7 day return of an 11.7% decline and a 30 day return of a 22.8% decline, set against a year to date return of 115.8% and a 1 year return of 271.6%, plus an increase of more than 7x over 3 years and 381.6% over 5 years. Recent...
NYSE:CIVI
NYSE:CIVIOil and Gas

Assessing Civitas Resources (CIVI) Valuation After Weaker Full Year 2025 Results

Full year 2025 earnings reset the conversation Civitas Resources (CIVI) recently reported full year 2025 results, with revenue of US$4,393 million and net income of US$561 million, both lower than the prior year, putting the stock back under closer investor review. See our latest analysis for Civitas Resources. At a share price of US$27.38, Civitas Resources has seen a 5.0% decline in its 90 day share price return and a 43.4% drop in its 1 year total shareholder return. This suggests momentum...
NYSE:IOT
NYSE:IOTSoftware

US Stock Market Today: S&P 500 Futures Fall On Higher Yields And Oil Surge

The Morning Bull - US Market Morning Update Monday, Mar, 9 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 1.3% and Nasdaq 100 futures off roughly 1.5%, as investors react to a jump in borrowing costs and energy prices. The US 10 year Treasury yield is around 4.22%, meaning mortgages, car loans, and corporate borrowing can all stay more expensive for longer, while oil above US$100 keeps pressure on fuel and transport costs. With Middle East...
NasdaqGS:BELF.A
NasdaqGS:BELF.AElectronic

Is It Time To Reassess Bel Fuse (BELF.A) After The Recent Share Price Pullback

If you are wondering whether Bel Fuse shares still offer value after a strong run, this article explains what the current price might be implying about the business. The stock closed at US$172.94 recently, with a 7 day return of an 18.4% decline and a 30 day return of a 16.0% decline, while the 1 year return sits at 119.7% and the 3 year return is very large. These price moves sit against a backdrop of ongoing attention on Bel Fuse within the tech sector, as investors reassess companies that...
NYSE:BRC
NYSE:BRCCommercial Services

Will Brady’s Higher Dividend Backed by Multi‑Year Cash Flow Growth Change Brady’s (BRC) Narrative?

On February 24, 2026, Brady Corporation’s board declared a US$0.245 per-share dividend on Class A common stock, payable April 30, 2026, to shareholders of record as of April 9, 2026. This dividend decision comes alongside multi-year growth in sales, earnings, and free cash flow, underscoring Brady’s capacity to return cash to investors. We’ll now examine how Brady’s dividend declaration, against a backdrop of solid multi-year earnings and cash flow growth, influences its investment...
NYSE:VRE
NYSE:VREResidential REITs

A Look At Veris Residential (VRE) Valuation After Recent Share Price Momentum

Recent share performance and business snapshot With no single headline event driving attention to Veris Residential (VRE), the recent share performance itself is the focus, as the stock shows double digit returns over the past month and past 3 months. Veris Residential is a real estate investment trust focused on Class A multifamily properties in the Northeast. It uses a technology enabled, vertically integrated platform to manage, operate, acquire, and develop its portfolio for residents and...
NasdaqGS:CERT
NasdaqGS:CERTHealthcare Services

How Investors Are Reacting To Certara (CERT) FDA Acceptance Of Simcyp In Place Of Clinical Trials

Certara recently highlighted that its Simcyp physiologically-based pharmacokinetic modeling was accepted by the U.S. FDA in place of multiple clinical pharmacology studies to support the new drug application for asciminib (Scemblix®), an allosteric BCR::ABL1 inhibitor for Chronic Myeloid Leukemia. This decade-long modeling effort, which replaced at least ten dedicated clinical studies and informed dosing and drug-interaction decisions, underscores how biosimulation can cut development costs...
NasdaqGS:MKTX
NasdaqGS:MKTXCapital Markets

Should MarketAxess’s New AI-Focused CTO Appointment Require Action From MarketAxess Holdings (MKTX) Investors?

MarketAxess Holdings Inc. recently appointed William Quan as Chief Technology Officer, tasking him with modernizing its global technology platforms and embedding AI and advanced data capabilities across the business. By bringing in a leader with deep experience in electronic trading and AI-driven platforms from firms like Amazon Web Services, J.P. Morgan, and Deutsche Bank, MarketAxess is signaling a stronger push to enhance its bond-trading technology and product innovation. With William...
NYSE:SES
NYSE:SESElectrical

SES AI (SES) Is Down 31.1% After Guiding Lower For 2026 And Pivoting From EV Batteries – Has The Bull Case Changed?

In early March 2026, SES AI Corporation reported full-year 2025 results showing sales of US$21.00 million, a smaller net loss of US$73.04 million, a Q4 revenue shortfall versus expectations, and new 2026 revenue guidance of US$30.00 million to US$35.00 million alongside a projected reset in gross margins. The earnings release also revealed a pivot away from automotive battery mass production toward energy storage systems, drones, and materials, while logistics-driven shipment delays and...
NYSE:VMC
NYSE:VMCBasic Materials

Vulcan Materials Faces Earnings Miss As Demand Concerns Lift Bearish Bets

Vulcan Materials (NYSE:VMC) reported quarterly results that came in below expectations, alongside softer guidance for the near term. J.P. Morgan downgraded the stock and flagged the possibility that demand growth could stay subdued until 2027. Short interest in Vulcan Materials has risen, pointing to increased bearish positioning in the shares. Vulcan Materials, trading at $274.99, is coming off a tough stretch, with the stock down 11.3% over the past week and 15.1% over the past month...
NasdaqCM:ALTO
NasdaqCM:ALTOChemicals

Alto Ingredients (ALTO) Is Up 92.5% After Returning To Profit On Clean Fuel Tax Credit Benefits

In early March 2026, Alto Ingredients reported fourth-quarter 2025 sales of US$231.97 million and net income of US$21.81 million, marking a shift from a loss a year earlier and delivering positive earnings per share for both the quarter and full year. This earnings release highlighted how portfolio realignment, improved crush margins, higher-value renewable fuel exports, and benefits from the 45Z clean fuel production credit collectively turned prior losses into profit across Alto’s...
NasdaqGS:USLM
NasdaqGS:USLMBasic Materials

United States Lime & Minerals (USLM) Valuation After ISM Manufacturing Report And Margin Expansion Expectations

United States Lime & Minerals (USLM) jumped 9.9% after the February ISM Manufacturing report highlighted rising input prices, which investors interpreted as potential pricing power and margin support for industrial suppliers. See our latest analysis for United States Lime & Minerals. That ISM driven jump comes on top of a 1 year total shareholder return of 30.39% and a very large 3 year total shareholder return of 294.55%, even though the year to date share price return is slightly negative...
NYSE:AMH
NYSE:AMHResidential REITs

The Bull Case For American Homes 4 Rent (AMH) Could Change Following Share Buyback And Softer Rental Demand

In late February and early March 2026, analysts including Citi, Raymond James, and Barclays turned more cautious on American Homes 4 Rent, citing softer rental demand, elevated new supply, and rising concessions across single-family and multifamily markets. At Citi’s Miami Global Property CEO Conference 2026, American Homes 4 Rent outlined its response with a new US$500 million share repurchase authorization and plans to develop about 1,900 homes in 2026 while closely tracking legislative...
NasdaqGS:SWBI
NasdaqGS:SWBILeisure

A Look At Smith & Wesson (SWBI) Valuation After Quarterly Earnings And Dividend Announcement

Quarterly earnings and dividend catch investors’ attention Smith & Wesson Brands (SWBI) recently reported third quarter results alongside a fresh dividend announcement. This gives investors new data on both operating performance and direct cash returns. For the quarter ended January 31, 2026, sales were US$135.71 million compared with US$115.89 million a year earlier, while net income was US$3.75 million versus US$2.10 million. See our latest analysis for Smith & Wesson Brands. The earnings...
NasdaqGS:DSGR
NasdaqGS:DSGRTrade Distributors

Assessing Distribution Solutions Group (DSGR) Valuation After Earnings Miss And Rising Legal Scrutiny

What triggered the latest move in Distribution Solutions Group? Distribution Solutions Group (DSGR) is back in focus after its fourth quarter and full year 2025 earnings missed analyst expectations on both revenue and earnings, pressuring margins and sparking legal scrutiny following a sharp share price reaction. See our latest analysis for Distribution Solutions Group. The sharp post earnings drop has fed into a wider reset in expectations, with a 7 day share price return of 26.12% and a...
NasdaqCM:MOBX
NasdaqCM:MOBXSemiconductor

Mobix Labs (MOBX) Is Up 530.3% After New Defense-Aerospace Orders and Quorum Shift - Has The Bull Case Changed?

In early March 2026, Mobix Labs, Inc. reported new production purchase orders for its high-reliability electromagnetic interference protection components used in Gulfstream business jets and the U.S. Navy’s Tomahawk cruise missile program, alongside a change to its bylaws reducing the shareholder meeting quorum requirement to one-third of voting power. The fresh aerospace and defense orders underline Mobix Labs’ role as an already-qualified supplier embedded in mission-critical platforms...
NasdaqGS:CWST
NasdaqGS:CWSTCommercial Services

Is Casella Waste Systems (CWST) Fairly Priced After Recent Share Price Pullback?

If you are wondering whether Casella Waste Systems at around US$94.03 is a fair deal or a stretch, you are not alone. This article focuses squarely on what the current price might imply about value. The stock has moved 0.9% over the past week, while showing a 10.1% decline over 30 days, a 4.7% decline year to date, a 16.4% decline over 1 year, but gains of 24.7% over 3 years and 45.3% over 5 years. Recent price moves sit against a backdrop where investors are watching the waste and recycling...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit Swing - What's Changed

CorMedix Inc. has reported past fourth-quarter 2025 revenue of US$128.62 million and net income of US$14.02 million, capping a year in which full-year revenue reached US$311.71 million and net income swung to US$163.06 million from a prior loss. The company’s reiteration of 2026 net revenue guidance of US$300 million to US$320 million, alongside advancing late-stage trials for REZZAYO and other pipeline assets, highlights management’s focus on consolidating recent product gains while...
NasdaqGM:PDYN
NasdaqGM:PDYNMachinery

A Look At Palladyne AI (PDYN) Valuation After 2026 Guidance And Backlog Expansion

Palladyne AI (PDYN) is back in focus after reporting Q4 and full year 2025 results, along with a fresh look at its 2026 outlook that combines earnings, guidance and backlog updates in one announcement. See our latest analysis for Palladyne AI. The latest earnings and guidance update landed after a sharp run in the shares, with a 7 day share price return of 21.34% and a 90 day share price return of 55.94% that point to building momentum despite a 14.36% pullback in the last session. The 3 year...
NYSE:RNST
NYSE:RNSTBanks

Earnings Beat, Dividend Hike and Insider Sale Could Be A Game Changer For Renasant (RNST)

In early March 2026, Renasant reported fourth-quarter 2025 results that beat analyst expectations, approved a US$0.23 per share quarterly dividend for payment on March 31, 2026, and disclosed an insider sale of 1,350 shares by EVP and Chief Accounting Officer Kelly Hutcheson. At the same time, investors grew more cautious about regional banks’ exposure to opaque private credit after a peer’s large loan write-off raised questions about hidden balance sheet risks across the sector. Against...
NasdaqGS:NSSC
NasdaqGS:NSSCElectronic

Is Napco Security Technologies’ (NSSC) Recurring Revenue Pivot Quietly Redefining Its Investment Story?

Napco Security Technologies recently presented at the 47th Annual Raymond James Institutional Investor Conference in Orlando, highlighting its electronic security solutions business and long-term roadmap. The company’s focus on high-margin recurring revenue and ongoing analyst interest in its operating performance has put its evolving business model under a brighter spotlight. Next, we’ll examine how this renewed analyst confidence around recurring revenue growth could influence Napco...
NYSE:AI
NYSE:AISoftware

C3.ai Lawsuits Put Legal Risks And Valuation In Sharper Focus

C3.ai (NYSE:AI) is under legal scrutiny after shareholders filed lawsuits alleging securities law violations and breaches of fiduciary duty. The actions follow disappointing financial results, a challenging CEO transition, and claims that material adverse information about sales and growth prospects was not properly disclosed. Regulatory and legal investigations are ongoing, raising questions about the company’s governance and leadership oversight. C3.ai, trading at $9.19, is in the...
NasdaqCM:NUTX
NasdaqCM:NUTXHealthcare

Assessing Nutex Health (NUTX) Valuation After Q4 Earnings Miss And New Share Repurchase Program

Nutex Health (NUTX) is back in focus after reporting full year 2025 results and unveiling a fresh share repurchase program, pairing weaker Q4 numbers with a new commitment to buying back stock. See our latest analysis for Nutex Health. The Q4 earnings miss and new buyback plan landed against a sharp reset in sentiment. A 90 day share price return of 50.14% decline and year to date share price return of 39.08% decline contrast with a 1 year total shareholder return of 102.15%, suggesting...